Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. - Wikidata - awgldk - TriplyDB

Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort.

Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort.

http://www.wikidata.org/entity/Q34479088

about

Almanac 2015: atrial fibrillation research in Heart Link Between Non-Alcoholic Fatty Liver Disease and Atrial Fibrillation: A Systematic Review and Meta-Analysis.Nonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis.Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study).Metabolomics and Incidence of Atrial Fibrillation in African Americans: The Atherosclerosis Risk in Communities (ARIC) Study Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure.γ-Glutamyltransferase and Risk of Sudden Cardiac Death in Middle-Aged Finnish Men: A New Prospective Cohort Study.Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure Association of the Aspartate Aminotransferase to Alanine Aminotransferase Ratio with BNP Level and Cardiovascular Mortality in the General Population: The Yamagata Study 10-Year Follow-Up.Gamma-glutamyl transferase and cardiovascular disease.Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.Baseline and long-term gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middle-aged Finnish men: Prospective study and pooled analysis of published evidence.Gamma-glutamyltransferase-friend or foe within?Liver enzymes are not directly involved in atrial fibrillation: a prospective cohort study.Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study.Circulating ceruloplasmin, ceruloplasmin-associated genes, and the incidence of atrial fibrillation in the atherosclerosis risk in communities study.Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets NAFLD/NASH in patients with type 2 diabetes and related treatment options.

P2860

Q26770598-D2774155-3B8C-4C20-918A-7557B7166172 Q33643887-AD099D4C-336F-48DF-98E6-D0E3E8EA4445 Q33805278-CE7EE343-301F-44E0-A4BC-1C916B342D29 Q35841934-DE854001-1DE6-4D4A-806A-E34ABCFF4B4A Q36257878-75E9C020-3DB5-4027-AEB7-0DFEC6952C36 Q36306272-1DDAAC71-9D65-4E24-8C26-39AA3CE6A364 Q36714040-0790AEE1-3819-497E-AB76-5CF67EDC3B1E Q37206133-523B2F47-3F47-48A6-9B63-51421C3B8094 Q37411680-FC2DD3F6-C53B-432F-B1C7-F060E25EC004 Q37583757-9A2AA03C-691F-4651-A9B4-774589833DD1 Q38711424-83B478A6-E292-4F57-A5FB-BC2109319EA3 Q38880366-C7680F1E-31AA-47D5-AACC-A68992515611 Q38924608-43CBEB74-6772-4D1C-8796-BE9EB4A70EC3 Q40140195-84D77D75-7C8E-4EF2-A805-680436303817 Q40218239-4F60772C-56F1-4861-97BB-ACB6356D5A9F Q40233926-5B2B2459-B669-409C-B79F-5930CFF714B2 Q41694135-A9BA68EF-595A-4B0C-81AD-ACD4C7B8127F Q47592767-753EFC8F-7803-4BC3-83D4-4AD983CFADA4

P2860

Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort.

http://www.wikidata.org/entity/Q34479088

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Circulating levels of liver en ...... is Risk in Communities cohort.

@ast

Circulating levels of liver en ...... is Risk in Communities cohort.

@en

Circulating levels of liver en ...... is Risk in Communities cohort.

@nl

type

label

Circulating levels of liver en ...... is Risk in Communities cohort.

@ast

Circulating levels of liver en ...... is Risk in Communities cohort.

@en

Circulating levels of liver en ...... is Risk in Communities cohort.

@nl

prefLabel

Circulating levels of liver en ...... is Risk in Communities cohort.

@ast

Circulating levels of liver en ...... is Risk in Communities cohort.

@en

Circulating levels of liver en ...... is Risk in Communities cohort.

@nl

P1433

Q34479088-162317D1-4D32-4175-A296-2C4DA1B8ED2C

P1476

Q34479088-410C4AC3-D7AA-4B1D-A8F2-9B06122902CB

P2093

Q34479088-0B21344F-30C6-49A1-BA32-103C8C2A1C7A

Q34479088-1B83C0A4-0CDE-4CD9-8DC8-665EE8F05829

Q34479088-34CDD004-D0EC-4CDA-AFBD-D1F1103D4DDC

Q34479088-53F7A02B-4AB0-4AA8-BF9F-D494272773CE

Q34479088-A1CF4112-08CA-4B9C-8F5E-453D7C56DA0D

Q34479088-FEAD40B3-37DF-4723-BE87-880E0BF4E15F

P2860

Q34479088-00F7CFC4-DA55-44F7-8892-323E7D0BCB49

Q34479088-015E99F1-36A8-4D35-B3CB-1DE2A6DA3B20

Q34479088-19770DAD-5BEF-4D13-979C-C27549AC8B50

Q34479088-2079C703-3263-41A3-B5C3-56DDF85976A9

Q34479088-2187A085-32FC-4ED5-A09F-AB3B77AB7751

Q34479088-2214CA89-2578-4362-ADC0-4F1C556962F7

Q34479088-367E2D5C-D2C0-4EDA-9598-18CD312ABE75

Q34479088-36C9D6C3-6E14-4C39-8211-EA4274ACCEEE

Q34479088-38AF5DF3-E2CA-4901-B794-54CA7D8E0241

Q34479088-409618DA-B421-4456-961D-E8357A026F7A

P304

Q34479088-2E537FAA-54AC-4CAD-94A5-0FEFFEA13441

P31

Q34479088-1E5F8B54-C254-4497-976F-5456425A2038

P356

Q34479088-039958BF-7220-486A-8853-D5F90D59C808

P407

Q34479088-BB5D820D-4E07-4DF4-B235-53AF7B6E79DA

P433

Q34479088-DE37C88F-A56B-4422-99CC-589A1E9F4D2B

P478

Q34479088-64A793AE-817D-4F1E-BEF2-B8F2FEDDBD3E

P50

Q34479088-18FA4BDE-E090-4D63-B7B2-FD58EECAC157

Q34479088-8CF5DC13-B036-4AC0-A379-A1DE75E86D28

Q34479088-CAC6A9C8-C51D-4F3B-BA47-463FAD5C714A

P577

Q34479088-AE70F89F-A3AB-46DF-A863-2A5FF70BFA5D

P698

Q34479088-64FD2680-D120-4181-B0A6-AB60B603151C

P921

Q34479088-0D2BA6BC-2232-4F3E-9F7F-4F772976434F

P932

Q34479088-311CEFD5-7724-4E58-8BE9-45BD8D6DFC62

P356

HEARTJNL-2014-305756

P1433

P1476

Circulating levels of liver en ...... is Risk in Communities cohort.

@en

P2093

Elsayed Z Soliman

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Misialek

http://www.w3.org/2001/XMLSchema#string

Laura R Loehr

http://www.w3.org/2001/XMLSchema#string

Lin Y Chen

http://www.w3.org/2001/XMLSchema#string

Mohamed A Amiin

http://www.w3.org/2001/XMLSchema#string

Sunil K Agarwal

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of validated methods for identifying atrial fibrillation using administrative data

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators

Nonalcoholic fatty liver disease

Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study

Evaluation of abnormal liver-enzyme results in asymptomatic patients.

Heart diseases affecting the liver and liver diseases affecting the heart.

Diet and risk of atrial fibrillation – epidemiologic and clinical evidence –.

Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase.

Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.

P304

1511-1516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HEARTJNL-2014-305756

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Ron C Hoogeveen

Elizabeth Selvin

P577

2014-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24924619

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

4225783

http://www.w3.org/2001/XMLSchema#string